Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if pre-incisional lidocaine injection, instilled liquid bupivacaine, intra-abdominal aerosolized bupivacaine, or post-operative bupivacaine injection is superior in post-operative pain control in laparoscopic bariatric surgical patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain, Postoperative Morbid Obesity |
Drug: Injected bupivacaine post-operatively Drug: Streamed bupivacaine versus streamed normal saline Drug: Aerosolized bupivacaine versus aerosolized saline Drug: Injected lidocaine pre-incision vs saline pre-incision |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Evaluation of Aerosolized Bupivacaine Versus Pre-incision Lidocaine Versus Instilled Liquid Bupivacaine Versus Post-operative Bupivacaine Injection for Optimization of Post-operative Pain Control in Laparoscopic Bariatric Surgical Patients |
- Measure of reduction in post-operative pain and narcotics usage. [ Time Frame: First 3 days post-operatively. ] [ Designated as safety issue: No ]
| Enrollment: | 100 |
| Study Start Date: | June 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 3 |
Drug: Streamed bupivacaine versus streamed normal saline
Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Other Names:
|
| Experimental: 2 |
Drug: Injected lidocaine pre-incision vs saline pre-incision
Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Other Names:
|
| Experimental: 4 |
Drug: Aerosolized bupivacaine versus aerosolized saline
Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Other Names:
|
| Active Comparator: 1 |
Drug: Injected bupivacaine post-operatively
Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Other Name: bupivacaine
|
Detailed Description:
The research objective is to compare our standard post-operative port site injection of 0.5% bupivacaine against pre-incisional port site injection of 1% lidocaine against the instillation of streamed bupivacaine 0.5% against the instillation of aerosolized 0.5% bupivacaine as it relates to post-operative analgesia usage and pain scale scores. The null hypothesis will be that there is no difference between the four arms of the study in regards to pain score and analgesia usage.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male and female patients between 18 and 65 years of age.
- Patients undergoing elective bariatric surgery.
Exclusion Criteria:
- Patients allergic to bupivacaine or any other local anesthetics (amides & esters).
- Patients who have used opiates or opiods within 15 days prior to surgery.
- Patients converted to open gastric bypass.
Contacts and Locations| United States, Pennsylvania | |
| Pinnacle Health; Community General Osteopathic Hospital | |
| Harrisburg, Pennsylvania, United States, 17109 | |
| Principal Investigator: | Troy A Moritz, DO | Pinnacle Health; Community General Osteopathic Hospital |
More Information
Publications:
| Responsible Party: | Troy Moritz, D.O., Troy Moritz DO, Pinnacle Health System |
| ClinicalTrials.gov Identifier: | NCT00508976 History of Changes |
| Other Study ID Numbers: | PHH#07-005 |
| Study First Received: | July 26, 2007 |
| Last Updated: | May 9, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Pinnacle Health System:
|
bupivacaine marcaine lidocaine normal saline narcotics |
analog pain scale postoperative pain preemptive aerosolization streamed |
Additional relevant MeSH terms:
|
Obesity Obesity, Morbid Pain, Postoperative Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Postoperative Complications Pathologic Processes Pain Anesthetics, Local |
Bupivacaine Lidocaine Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Arrhythmia Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 19, 2013